183 related articles for article (PubMed ID: 19147089)
21. Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Mesa RA
Biologics; 2007 Jun; 1(2):129-38. PubMed ID: 19707323
[TBL] [Abstract][Full Text] [Related]
22. Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study.
Ahmed A; Powers MP; Youker KA; Rice L; Ewton A; Dunphy CH; Chang CC
Pathol Res Pract; 2009; 205(9):634-8. PubMed ID: 19446406
[TBL] [Abstract][Full Text] [Related]
23. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in understanding myelofibrosis and essential thrombocythemia.
Vainchenker W; Constantinescu SN; Plo I
F1000Res; 2016; 5():. PubMed ID: 27134742
[TBL] [Abstract][Full Text] [Related]
25. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
26. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.
Htun HL; Lian W; Wong J; Tan EJ; Foo LL; Ong KH; Lim WY
Cancer Epidemiol; 2022 Aug; 79():102175. PubMed ID: 35569302
[TBL] [Abstract][Full Text] [Related]
27. Deactylase inhibition in myeloproliferative neoplasms.
Mithraprabhu S; Grigoriadis G; Khong T; Spencer A
Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S50-7. PubMed ID: 21127942
[TBL] [Abstract][Full Text] [Related]
28. The history of myeloproliferative disorders: before and after Dameshek.
Tefferi A
Leukemia; 2008 Jan; 22(1):3-13. PubMed ID: 17882283
[TBL] [Abstract][Full Text] [Related]
29. Inheritance of the chronic myeloproliferative neoplasms. A systematic review.
Ranjan A; Penninga E; Jelsig AM; Hasselbalch HC; Bjerrum OW
Clin Genet; 2013 Feb; 83(2):99-107. PubMed ID: 23094849
[TBL] [Abstract][Full Text] [Related]
30. Atypical myeloproliferative disorders: diagnosis and management.
Tefferi A; Elliott MA; Pardanani A
Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
[TBL] [Abstract][Full Text] [Related]
31. [New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3295-9. PubMed ID: 17032591
[TBL] [Abstract][Full Text] [Related]
32. Cytogenetics of myeloproliferative neoplasms.
Campbell LJ
Methods Mol Biol; 2011; 730():89-98. PubMed ID: 21431636
[TBL] [Abstract][Full Text] [Related]
33. [Chronic myeloid neoplasms. Diagnostic criteria and current therapeutic concepts].
Schmitt-Graeff AH
Pathologe; 2010 Feb; 31(1):29-41. PubMed ID: 20076959
[TBL] [Abstract][Full Text] [Related]
34. Myeloproliferative disorders.
Bench AJ; Cross NC; Huntly BJ; Nacheva EP; Green AR
Best Pract Res Clin Haematol; 2001 Sep; 14(3):531-51. PubMed ID: 11640868
[TBL] [Abstract][Full Text] [Related]
35. Philadelphia Chromosome Positive Chronic Myelogenous Leukemia Blastic Crisis in A Patient with Unusual Primary Myelofibrosis Characteristics; A Case Report.
Razmara Lak E; Sharifzadeh S; Ramzi M; Mokhtari M; Asadpouri R; Abedi E; Tamaddon G
Cardiovasc Hematol Agents Med Chem; 2023 Jun; ():. PubMed ID: 37317905
[TBL] [Abstract][Full Text] [Related]
36. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic and tumor suppressor genes expression in myeloproliferative neoplasms: The hidden side of a complex pathology.
Abedi E; Karimi M; Yaghobi R; Mohammadi H; Haghpanah S; Moghadam M; Bayat E; Rezvani A; Ramzi M
J Clin Lab Anal; 2022 Apr; 36(4):e24289. PubMed ID: 35176183
[TBL] [Abstract][Full Text] [Related]
38. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
Hasselbalch HC
Leuk Res; 2009 Jan; 33(1):11-8. PubMed ID: 18632152
[TBL] [Abstract][Full Text] [Related]
39. Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases.
Wong WS; Cheng KC; Lau KM; Chan NP; Shing MM; Cheng SH; Chik KW; Li CK; Ng MH
Leuk Res; 2007 Feb; 31(2):235-8. PubMed ID: 16777224
[TBL] [Abstract][Full Text] [Related]
40. Shooting the messenger: targeting signal transduction pathways in leukemia and related disorders.
Noor SM; Bell R; Ward AC
Crit Rev Oncol Hematol; 2011 Apr; 78(1):33-44. PubMed ID: 20570172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
